


## Delavirdine

<b>Cat. No.:</b>	HY-10571
<b>CAS No.:</b>	136817-59-9
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>28</sub> N <sub>6</sub> O <sub>3</sub> S
<b>Molecular Weight:</b>	456.56
<b>Target:</b>	HIV; Reverse Transcriptase
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Delavirdine (U 90152) is a potent, highly specific and orally active non-nucleoside reverse transcriptase inhibitor (NNRTI). Delavirdine selectively inhibits HIV-1 reverse transcriptase (RT) (IC <sub>50</sub> =0.26 μM) over DNA polymerase α (IC <sub>50</sub> =440 μM) and polymerase δ (IC <sub>50</sub> >550 μM). Delavirdine is an inhibitor of HIV-1 replication and can be used for the study of AIDs <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 0.26 μM (HIV-1 RT); 440 μM (DNA polymerase α); >550 μM (DNA polymerase δ) <sup>[1]</sup>
<b>In Vitro</b>	Delavirdine has an 50% cytotoxicity at concentrations >100 μM in H9 and PBMC cultures. Delavirdine has low cellular cytotoxicity, causing less than 8% reduction in peripheral blood lymphocyte viability at 100 μM <sup>[1]</sup> . Delavirdine inhibits HIV-1 reverse transcriptase (RT) wild type with an IC <sub>50</sub> value of 0.26 μM, and it inhibits Y181C-substituted RT and K103N-substituted RT with IC <sub>50</sub> values of 8.32 μM and 7.7 μM, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Delavirdine (U 90152) (oral gavage; 10 mg/kg, 200 mg/kg, 250 mg/kg; single dose) is absorbed and metabolized rapidly, that it constitutes a minor component in circulation, that its pharmacokinetics are nonlinear, and that its metabolism to desalkyl delavirdine is capacity limited or inhibitable in CD-1 mice (PK study) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- Int J Antimicrob Agents. 2019 Dec;54(6):814-819.
- Sci Rep. 2015 Oct 29;5:15806.
- Future Med Chem. 2018 Dec 17.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

[1]. Dueweke TJ, et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 1993 May;37(5):1127-31.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA